International Linked Clinical Trials (iLCT)
25 results.
Earlier this week, The Lancet published results of a phase 3 clinical trial that explored whether the Type 2 diabetes medication exenatide could…
The past year at Van Andel Institute can be summed up in two words: “growth” and “impact.”
We’ve expanded our research capacity by adding new…
In September, Van Andel Institute welcomed nearly 300 scientists, physicians and people with Parkinson’s for our annual Grand Challenges in Parkinson’s Disease symposium and Rallying…
LONDON (May 29, 2024) — Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce funding for…
LONDON (April 3, 2024) — Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may…
LONDON (Feb. 23, 2024) — Cure Parkinson’s and Van Andel Institute are delighted to announce funding for a Phase 2 clinical trial…
Copenhagen, Denmark (August 28, 2023) — A one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide has reported positive early results, which indicate…
Grand Rapids, Mich. (March 13, 2023) — Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement, which supports…